Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Trial Profile

Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2017 Planned primary completion date changed from 1 Apr 2022 to 30 Apr 2022.
    • 23 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top